Mass General Brigham evaluates AI tools by carefully monitoring real-world performance before scaling them system-wide. At HIMSS earlier this month, Rebecca Mishuris, the health system’s chief health information officer and vice president of digital, explained what this process looks like.
Michael Meucci, CEO of health data platform Arcadia, thinks health systems are changing their thinking about ROI when it comes to AI projects. As providers face tighter budgets, he said they’re broadening how they measure AI’s ROI, including benefits like reducing clinician burnout.
Artera President Tom McIntyre talks about the practical application of AI in healthcare.
Fawad Butt, CEO of Penguin Ai, gave his candid thoughts on where the healthcare AI market is headed, including how data leakage could be fueling smarter AI models and the limits of agentic AI in enterprise settings.
At Wayne General Hospital in rural Mississippi, clinicians are using Eko Health’s AI-powered digital stethoscope to detect heart conditions earlier in patients with limited access to specialists.
Utah is piloting an AI system developed by Doctronic to autonomously handle routine prescription refills, aiming to reduce delays and boost medication adherence. But a report from Mindgard AI claiming that there are vulnerabilities in the company’s chatbot underscores the broader challenge regulators and developers face in ensuring healthcare AI systems remain safe and reliable in real-world use.
Katie Jacobs Stanton, founder of Moxxie Ventures, shared some details of how she and her team evaluate healthcare AI startups. She stressed the need for founders with deep industry expertise, differentiated products and realistic distribution strategies.
Arbiter’s Anjali Jameson on hospital and payer alignment.
Epic has unveiled its new “agent factory,” a platform that lets health systems build AI agents that are capable of orchestrating entire workflows across the EHR.
Waiv, formerly the diagnostics division of AI biotech Owkin, developed AI-enabled testing technologies that found use in clinical settings and in cancer drug research. Spinning out as an independent company enables Waiv to pursue its own growth strategy, co-founder and CEO Meriem Sefta said.
Flagship Pioneering-founded Generate Biomedicines aims to offer less frequent injections compared to a blockbuster asthma drug from partners Amgen and AstraZeneca. Generate’s drug comes from a “programable biology” platform technology that uses AI and machine learning to design proteins with desirable properties.
OpenAI announced a new dedicated platform for health conversations. The company said the new offering is not intended for medical diagnosis or treatment — but rather to provide support for personal health navigation.
Zelis highlights how employers, payers, and consumers are integrating digital tools to manage healthcare costs.
New research shows that while health systems are pouring money into AI tools, most are still struggling to use the technology to meaningfully engage patients. Moving beyond generic outreach to “N-of-1 personalization” could be key to closing engagement gaps and improving patient outcomes at scale, said Amy Bucher, chief behavioral officer at Lirio.
Clinical decision support startup Aidoc has become a major player in healthcare AI thanks to its focus on acute, life-or-death cases and its R&D-first approach. As Aidoc continues to innovate, Chief Business Officer Tom Valent thinks its commitment to patient safety and transparency will be key contributors to future success.
Dr. Prajnan Das, department chair of Gastrointestinal (GI) Radiation Oncology at MD Anderson Cancer Center, talks about how precision medicine has evolved and how AI may actually be the technology that supercharges the conversion of the knowledge about human biology to personalized treatments that work.
Mass General Brigham spun out a new company offering a generative AI platform that can rapidly interpret both structured and unstructured clinical data. Right now, the tool’s primary application is to accelerate and improve the accuracy of patient screening for clinical trials.
Nvidia has quietly become one of the most influential players in healthcare technology by supplying the accelerated computing and AI infrastructure that powers everything from imaging to drug discovery. The company’s restraint — focusing on enabling the ecosystem rather than owning it — has helped cement its role as the indispensable backbone of the healthcare industry’s AI transformation.